Literature DB >> 20068400

Guardians at the gate: patent protection for therapeutic monoclonal antibodies--part 1.

Kevin W McCabe1.   

Abstract

Patents provide one of the few protections companies can avail themselves of to help protect their therapeutic monoclonal antibody products. Just as the therapeutic monoclonal antibody field is constantly evolving, so too is the legal environment surrounding these inventions. In a series of articles, the general state of the law surrounding therapeutic antibodies will be explained, and important challenges to this technology area will be discussed. Much is at stake when companies market therapeutic monoclonal antibodies; therefore, a firm understanding of this important form of protection is critically important for anyone developing such products.

Mesh:

Substances:

Year:  2009        PMID: 20068400      PMCID: PMC2726603          DOI: 10.4161/mabs.1.4.8860

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  4 in total

1.  European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.

Authors:  Janice M Reichert; Alain Beck; Harish Iyer
Journal:  MAbs       Date:  2009-09-25       Impact factor: 5.857

2.  Guardians at the gate: patent protection of therapeutic monoclonal antibodies through product life cycle management--Part 3.

Authors:  Kevin W McCabe; Paul A Calvo
Journal:  MAbs       Date:  2009-11-14       Impact factor: 5.857

3.  Intellectual property protection: strategies for antibody inventions.

Authors:  Ulrich Storz
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

4.  5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Authors:  Alain Beck; Janice M Reichert; Thierry Wurch
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.